Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Amid an expanding outbreak, Florida has confirmed its first dengue-related death in the Tampa Bay region. It is the first death due to dengue in Tampa Bay in almost a century, while Florida health officials have confirmed this as the state’s first dengue-related death of 2026.

The latest reports show the newest figures that indicate 152 locally acquired dengue cases as of September 12, with 134 in Hillsborough County.

First Dengue-Related Death In Florida

Florida’s dengue outbreak has turned deadly as with health officials have confirmed the state’s first dengue-related death of 2026.

The Florida Department of Health confirmed the death on September 18. The victim was an 80-year-old Hillsborough County woman who died on September 4. Her death marks the first known dengue-related fatality in the Tampa Bay region in nearly a century.

The latest state data, covering cases through September 12, show 152 locally acquired dengue infections across Florida this year, including 134 in Hillsborough County.

That means nearly 90% of the state's locally acquired cases have been concentrated in the county, which has emerged as the epicentre of the outbreak.

“This is wildly unusual for us,” Chris Wilkerson, a spokesperson for Hillsborough County, said.

Also read: QDENGA: India’s First Approved Dengue Vaccine May Hit Shelves In 2027; How Effective Is It?

Dengue Outbreak In Florida

Dengue is a viral infection transmitted mainly by infected Aedes aegypti and Aedes albopictus mosquitoes. These mosquitoes are established in Florida and can spread the virus after biting an infected person.

Majority of the dengue infections reported in the continental US were linked with international travel. But Florida has increasingly recorded locally acquired infections, meaning people contracted the virus without travelling to a dengue-endemic country.

The state reported its largest number of locally acquired dengue infections in 2023, at nearly 200. With 152 cases already recorded this year, 2026 has become the state's second-highest year for locally acquired infections.

Also read: Delhi Dengue Cases Rise In September: Is Weather Fueling The Surge?

How Can Dengue Become Life-Threatening?

Most people infected with dengue either have no symptoms or develop a relatively short-lived illness with fever, headache, muscle and joint pain, nausea and rash. But a small number of people can develop severe dengue, particularly around the time the fever begins to subside.

Warning signs include severe abdominal pain, persistent vomiting, bleeding or unusual bruising, difficulty breathing, extreme weakness and restlessness.

Severe dengue may also cause plasma leakage, shock, severe bleeding and organ damage, which can become fatal without prompt medical care.

In the Florida woman's case, her death certificate listed dengue infection, septic shock and multi-organ failure as causes, according to the Tampa Bay Times.

Florida Outbreak Is Raising Concern

Hillsborough County normally sees only a handful of dengue cases, making the current cluster seems to be highly unusual. Mosquito-control teams have increased aerial and ground surveillance and spraying, inspecting properties for stagnant water where mosquitoes can breed.

Recent mosquito sampling has not detected dengue virus in some of the latest collections, which officials say could indicate that transmission is beginning to decline. But experts caution that the mosquitoes capable of spreading dengue may still remain in Florida.

Michael von Fricken, an associate professor of environmental and global health at the University of Florida, said the state's recurring mosquito population means dengue may become “somewhat the new normal.”

Florida health officials are urging residents to use mosquito repellent, wearing long sleeves and trousers, and removing stagnant water from around homes.

In the trailer for the eighth season of The Kardashians, Kim Kardashian revealed that she has been diagnosed with esophagitis, a condition involving inflammation and irritation of the esophagus. The conversation sparked memories of her father Robert Kardashian, who died of esophageal cancer in 2003.

In the trailer, someone asks her, “Didn't your father ... isn't it what he died of?” to which she responds, “Yeah.”

Her mother, Kris Jenner, is also seen becoming emotional. Kardashian is shown in a hospital bed, although the trailer does not reveal the exact cause or severity of her esophagitis or any procedure she may have undergone.

But it is important to clarify that esophagitis and esophageal cancer are two different conditions.

What Is Esophagitis?

Esophagitis is a condition in which the lining of the esophagus, the tube that carries food and liquids from the mouth to the stomach, becomes inflamed.

There are several possible causes for the inflammation of the esophagus. The most common is gastroesophageal reflux disease (GERD), a condition in which stomach acid flows back into the esophagus repeatedly. Other causes include certain medications, infections and allergic or conditions related to immune system.

Symptoms can include heartburn, chest pain, painful or difficult swallowing, coughing, hoarseness and a sore throat.

The treatment for esophagitis depends on what is causing the inflammation and can include medicines that reduce stomach acid, treatment for an infection or changes to diet and other habits. The condition is often manageable with treatment.

Also read: Bruce Willis’ Dementia Diagnosis Left Wife Emma Heming Feeling ‘Lost’ And ‘Isolated’ - What Are The Signs Of Caregivers Burnout?

Does Esophagitis Increase Cancer Risk?

Esophagitis itself does not mean a person will develop esophageal cancer. The concern refers to when chronic acid reflux continues for years. Repeated exposure to stomach acid can damage the esophageal lining and, in some people, lead to Barrett's esophagus.

Barrett's esophagus involves changes in the cells lining the lower esophagus and is associated with an increased risk of esophageal adenocarcinoma, one of the major types of esophageal cancer. However, most people with Barrett's esophagus do not develop cancer.

Rather, in some people, long-standing reflux can cause chronic damage, which can lead to Barrett's esophagus, which in turn is associated with a higher cancer risk.

Also read: Busy Philipps Reveals She Had Surgery To Remove A Rare Brain Tumour: What Is Oligodendroglioma?

Kim Kardashian’s Family History

According to reports, Kim Kardashian's father Robert Kardashian died from esophageal cancer in September 2003 at the age of 59, only about two months after his diagnosis. This family history makes Kim's diagnosis particularly significant.

However, there is currently no public information showing that her esophagitis is hereditary or that it is connected to the cancer her father had. Her diagnosis also does not establish that she has Barrett's esophagus or esophageal cancer. The trailer does not disclose those details.

The Kardashian family has nevertheless remained involved in awareness about esophageal health since Robert's death. In 2019, the family helped establish the Robert G. Kardashian Center for Esophageal Health at UCLA, dedicated to research, treatment and education about diseases of the esophagus.

When Should Esophageal Symptoms Be Checked?

Persistent difficulty swallowing, painful swallowing, unexplained weight loss, recurrent vomiting, bleeding or discomfort in chest should not simply be dismissed as normal acidity.

Doctors may use tests such as an upper endoscopy to examine the esophagus and determine whether inflammation, structural changes or other abnormalities are present. Persistent inflammation, particularly when driven by untreated chronic reflux, can sometimes signal a problem that needs medical evaluation and follow-up.

A new study has found a way to identify which younger adults are most likely to develop severe liver damage decades earlier than expected, by looking at their genetics and whether they have type 2 diabetes. The finding could allow doctors to catch dangerous liver disease, and even begin cancer screening, years before symptoms would otherwise appear.

Doctors have long known that fatty liver disease can quietly damage the liver over many years. But this research shows that some people develop the most serious stage of this damage, cirrhosis, much earlier than expected, sometimes before they even turn 50. What makes this study significant is that it identifies exactly why: specific genetic factors combined with type 2 diabetes appear to accelerate the disease in these younger patients.

Researchers at the University of California San Diego School of Medicine carried out the study, and their findings were published on September 16 in the journal Clinical Gastroenterology and Hepatology. It is being described as the first study to properly define what early-onset cirrhosis from fatty liver disease actually looks like, and what sets these patients apart.

What the Researchers Found

The condition in question is called MASLD, short for metabolic dysfunction-associated steatotic liver disease. Most people know it simply as fatty liver disease. It develops when fat builds up in the liver, and over time, this can lead to scarring. In its most advanced form, that scarring becomes cirrhosis, a stage where liver damage is severe and often permanent.

To understand why some people reach this stage so early, the researchers studied close to 2,400 adults with confirmed cases of MASLD. All of them were part of a larger research group called the NASH Clinical Research Network. Among these patients, 25 percent who had cirrhosis had developed it before the age of 50.

The key finding is that these younger patients were not simply following the same disease path as older patients, only faster. Instead, two specific factors set them apart: inherited genetic risk and type 2 diabetes. This matters because it gives doctors something concrete to check for, rather than simply waiting to see who develops symptoms.

Rohit Loomba, the senior author of the study and a liver specialist at UC San Diego Health, explained that younger adults with cirrhosis appear to have a distinct mix of genetic and metabolic risk factors that speed up the disease. "Cirrhosis is frequently silent until serious complications develop," he said. "These results suggest that younger adults with type 2 diabetes, obesity or elevated genetic risk may benefit from more proactive liver assessment."

Also read: High Sugar, Salt Or Fat? India May Mandate Red Hexagon Labels On Food Packs

A Gap in Current Screening

This is where the study's findings become especially useful. Many of the standard tools used to assess liver fibrosis take a patient's age into account, which sounds reasonable on the surface but can actually work against younger patients who are already at risk.

The study found that nearly a third of the people with early-onset cirrhosis would not have been flagged as high risk under the usual screening methods. In other words, the tools meant to catch liver damage early are, in some cases, missing it entirely in younger adults, precisely the group this study identifies as vulnerable.

"As current screening tools incorporate age, they miss almost a third of patients with early-onset MASLD cirrhosis," said Veeral Ajmera, MD, first author of the study, hepatologist at UC San Diego Health, and associate professor of medicine at UC San Diego School of Medicine. "This study helps us identify which patients are at greatest risk and need a more accurate assessment of their liver disease."

Also read: Sugar-Free Sweetener Used In Candies May Have A Harmful Metabolic Effect On Liver: Is Sorbitol Really Healthy?

Why This Matters Going Forward

The value of identifying these patients early goes beyond liver health alone. Cirrhosis is one of the biggest known risk factors for liver cancer, so flagging high-risk individuals sooner, based on their genetics and diabetes status rather than their age, could allow doctors to begin cancer screening and treatment much earlier than they otherwise would.

With rates of obesity and type 2 diabetes continuing to climb across the world, researchers expect fatty liver disease to become even more common in the years ahead. Because of this, the study believes that younger adults who have diabetes, obesity, or a higher genetic risk may benefit from more careful and more frequent liver evaluations, rather than waiting for age-based warning signs that may never appear in time.